Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19

Article activity feed

1. Version published to 10.1016/j.biopha.2022.112753

   Apr 1, 2022
2. 

   ScreenIT

   Dec 30, 2021

   SciScore for 10.1101/2021.12.23.21268347: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	Consent: Participant’s next of kin were consented and signed the written informed consent on their behalf to participate in the investigation. IRB: This investigation was approved by the Santa Cruz State University (UESC) Institutional Brazilian Ethics Committee (Approval number: 45919121.6.0000.5526).
   Sex as a biological variable	Patient Samples: Tracheal aspirate (TA) samples (2-10mL) were collected during the early morning routine from 20 COVID-19 patients, aging from 18-80 years-old (male n=12) under mechanical ventilation at the intensive care unit of Hospital de Ilhéus.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources

   SciScore for 10.1101/2021.12.23.21268347: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	Consent: Participant’s next of kin were consented and signed the written informed consent on their behalf to participate in the investigation. IRB: This investigation was approved by the Santa Cruz State University (UESC) Institutional Brazilian Ethics Committee (Approval number: 45919121.6.0000.5526).
   Sex as a biological variable	Patient Samples: Tracheal aspirate (TA) samples (2-10mL) were collected during the early morning routine from 20 COVID-19 patients, aging from 18-80 years-old (male n=12) under mechanical ventilation at the intensive care unit of Hospital de Ilhéus.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Samples were diluted 1:10 and incubated with magnetic beads covered with monoclonal antibodies specific to several immunological mediators, such as: chemokines (CXCL8, CCL11, CCL3, CCL4, CCL2, and CXCL10), inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-12, IFN-γ, IL-15 and IL-17), regulatory cytokines (IL-1Ra, IL-9, IL-10) and growth factors (FGF-basic, PDGF, VEGF, G-CSF, GM-CSF, IL-2 and IL-7).	CXCL8 suggested: None CCL11 suggested: None CCL3 suggested: (Thermo Fisher Scientific Cat# EPX300-40044-901, RRID:AB_2576121) CCL4 suggested: (Thermo Fisher Scientific Cat# EPX300-40044-901, RRID:AB_2576121) CCL2 suggested: None CXCL10 suggested: None IL-6 suggested: None TNF-α suggested: (Bio-Rad Cat# M6000007NY, RRID:AB_2784537) IL-12, IFN-γ suggested: (Bio-Rad Cat# M60009RDPD, RRID:AB_2857368) IL-15 suggested: None IL-1Ra suggested: (BioLegend Cat# 741091, RRID:AB_2895549) IL-9 suggested: None IL-10 suggested: None FGF-basic, PDGF suggested: None G-CSF, GM-CSF suggested: None IL-2 suggested: None IL-7 suggested: None
   Software and Algorithms
   Sentences	Resources
   All the analysis were carried out using GraphPad Prism, version 8.0, (San Diego, CA, USA).	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.12.23.21268347v1 on medRxiv

   Dec 25, 2021